When to test fetuses for RASopathies? Proposition from a systematic analysis of 352 multicenter cases and a postnatal cohort
- 10 February 2021
- journal article
- research article
- Published by Elsevier BV in Genetics in Medicine
- Vol. 23 (6), 1116-1124
- https://doi.org/10.1038/s41436-020-01093-7
Abstract
No abstract availableFunding Information
- American International Recruitment Council (IG 21614, IG 21614, IG 21614, IG 21614)
This publication has 37 references indexed in Scilit:
- Enhanced MAPK1 Function Causes a Neurodevelopmental Disorder within the RASopathy Clinical SpectrumAmerican Journal of Human Genetics, 2020
- Germline and sporadic cancers driven by the RAS pathway: parallels and contrastsAnnals of Oncology, 2020
- Activating Mutations of RRAS2 Are a Rare Cause of Noonan SyndromeAmerican Journal of Human Genetics, 2019
- The RASopathy Family: Consequences of Germline Activation of the RAS/MAPK PathwayEndocrine Reviews, 2018
- Elucidation of MRAS-mediated Noonan syndrome with cardiac hypertrophyJCI Insight, 2017
- Expansion of the RASopathiesCurrent Genetic Medicine Reports, 2016
- Recent advances in RASopathiesJournal of Human Genetics, 2015
- Cancer spectrum and frequency among children with Noonan, Costello, and cardio-facio-cutaneous syndromesBritish Journal of Cancer, 2015
- Noonan syndrome and clinically related disordersBest Practice & Research Clinical Endocrinology & Metabolism, 2011
- Disorders of dysregulated signal traffic through the RAS‐MAPK pathway: phenotypic spectrum and molecular mechanismsAnnals of the New York Academy of Sciences, 2010